Replimune Ltd, a UK start-up, has raised $30 million in Series A finance to develop therapeutics based on the use of oncolytic viruses, or viruses that infect and destroy cancer cells. The funding round is being led by Atlas Venture with participation from Forbion Capital Partners and Omega Funds.
